GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incanthera PLC (AQSE:INC) » Definitions » ROCE %

Incanthera (AQSE:INC) ROCE % : 0.00% (As of Sep. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Incanthera ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Incanthera's annualized ROCE % for the quarter that ended in Sep. 2023 was 0.00%.


Incanthera ROCE % Historical Data

The historical data trend for Incanthera's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incanthera ROCE % Chart

Incanthera Annual Data
Trend Mar20 Mar21 Mar22 Mar23
ROCE %
-100.99 -69.95 -86.01 -256.34

Incanthera Semi-Annual Data
Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
ROCE % Get a 7-Day Free Trial -82.41 -102.34 -162.22 -520.58 -

Incanthera ROCE % Calculation

Incanthera's annualized ROCE % for the fiscal year that ended in Mar. 2023 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2023 )  (A: Mar. 2022 )(A: Mar. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2023 )  (A: Mar. 2022 )(A: Mar. 2023 )
=-0.96/( ( (1.028 - 0.196) + (0.197 - 0.28) )/ 2 )
=-0.96/( (0.832+-0.083)/ 2 )
=-0.96/0.3745
=-256.34 %

Incanthera's ROCE % of for the quarter that ended in Sep. 2023 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Sep. 2023 )  (Q: Mar. 2023 )(Q: Sep. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Sep. 2023 )  (Q: Mar. 2023 )(Q: Sep. 2023 )
=-1.23/( ( (0.197 - 0.28) + (0.161 - 0.633) )/ 2 )
=-1.23/( ( -0.083 + -0.472 )/ 2 )
=-1.23/-0.2775
=0 %

(1) Note: The EBIT data used here is two times the semi-annual (Sep. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Incanthera  (AQSE:INC) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.


Incanthera ROCE % Related Terms

Thank you for viewing the detailed overview of Incanthera's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Incanthera (AQSE:INC) Business Description

Traded in Other Exchanges
N/A
Address
76 King Street, Manchester, GBR, M2 4NH
Incanthera PLC is a specialist dermatology and oncology company focused on transforming cancer treatment by creating environments in which cancer cannot survive. It identifies and develops solutions to current clinical, commercially relevant unmet needs, utilising a new technology. The company's current products are Sol, EP0015, Equin and Duo-C. The company has one segment, namely the development of pharmaceutical products all within the United Kingdom.

Incanthera (AQSE:INC) Headlines

No Headlines